CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation.
News
GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif., May 11, 2020 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to e… […]
News
GenMark Diagnostics Schedules Second Quarter 2019 Financial Results Conference Call for August 5, 2019
CARLSBAD, Calif., July 22, 2019 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on?Monday, August 5, 2019. Management will hold a conference … […]
News
GenMark Diagnostics Schedules Third Quarter 2019 Financial Results Conference Call for November 6, 2019
CARLSBAD, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on?Wednesday, November 6, 2019. Management will hold a confere… […]
